Overview

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Status:
Recruiting

Trial end date:
2027-10-20

Target enrollment:

Participant gender:

Summary

This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma

Phase:

Phase 2

Details

Lead Sponsor:

Wuhan Union Hospital, China

Treatments:

Bortezomib
Cyclophosphamide
Daratumumab
Dexamethasone
Epirubicin
Etoposide
Lenalidomide
Melphalan